- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06223971
Long COVID-19 [11C]CPPC Study
A Phase l Study to Assess the Safety and Tolerability of PET Imaging With [11 C]CPPC [5-cyano-N-( 4-( 4-[l l CJ me1hylpiperazin-l-yl)-2-(Piperidin-l-yl)Phenyl)Furan-2-carboxamide] Radioligand and Magnetic Resonance (MR) Imaging in Patients With Long COVID.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Mehreen Nabi, MBBS
- Phone Number: 4109296586
- Email: mnabi1@jh.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins Outpatient Center
-
Contact:
- Mehreen Nabi, MBBS
-
Principal Investigator:
- Licia Luna, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures.
- Documented history of COVID infection at least 6 - 12 months before enrollment.
- Men and women at least 18 years old.
- Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization).
- Geographic accessibility to the study center and the ability to travel to the clinic for study visits.
- Agrees to the visit schedule as outlined in the informed consent.
- Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator.
Exclusion Criteria:
- History of recent nosocomial infection.
- History of chronic neurological disorder, such as epilepsy, or structural Central Nervous System (CNS) abnormality such as stroke or arteriovenous malformation.
- History of head trauma with prolonged loss of consciousness (>10 minutes) or any neurological condition including stroke, seizure (excluding childhood febrile seizure), or visible structural abnormality on prior MRI.
- Active or recent (in the past year) substance dependence (drugs-including nicotine, marijuana or alcohol).
- Receipt of any investigational drug, device or biologic within 30 days of administration of study compound.
- Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines within 7 days of administration of study compound.
Any concomitant medical disease or condition limiting the safety to participate including, but not limited to:
- Coagulopathy
- Active infection
- Contraindications to MRI scanning to include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc.
- Contraindications to PET scanning to include pregnancy, etc.
- Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
- Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem.
- Any history of learning disability or special education (due to the potential to affect performance on neuropsychological testing).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with history of COVID-19 infection and still experiencing symptoms (Long-COVID)
Participants with a diagnosis of Long- COVID will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
|
A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan. Other Name: [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide] |
Experimental: Healthy Participants with history of COVID-19 infection but not experiencing any symptoms.
Healthy participants (without any history of post-COVID symptoms) will receive a single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
|
A single dose of [11C]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan. Other Name: [5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide] |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the safety and tolerability of one dose level of [11C]CPPC when administered intravenously.
Time Frame: Baseline and up to 2 days follow-up after scan
|
Safety and tolerability will be determined by evaluation of spontaneously reported adverse events, clinical laboratory test results, physical, cognitive and neurologic exams and imaging (PET).
|
Baseline and up to 2 days follow-up after scan
|
Safety of use of [11C]CPPC in patients with Long-COVID and healthy participants with history of COVID-19 infection as assessed by a change in complete blood count (CBC) test.
Time Frame: Baseline and up to 2 days follow-up after scan
|
Safety of use of [11C]CPPC in positron emission tomography (PET) neuroimaging of patients with Long-Covid and healthy participants with history of COVID-19 infection.
Safety will be assessed by monitoring of the complete blood count (CBC) for a change from baseline that is outside of the normal range.
|
Baseline and up to 2 days follow-up after scan
|
Safety of use of [11C]CPPC in patients with Long-COVID and healthy participants with history of COVID-19 infection as assessed by a change in complete metabolic panel (CMP) test.
Time Frame: Baseline and up to 2 days follow-up after scan
|
Safety of use of [11C]CPPC in positron emission tomography (PET) neuroimaging of patients with Long-COVID and healthy participants with history of COVID-19 infection.
Safety will be assessed by a change in the CMP from baseline that is outside of the normal range
|
Baseline and up to 2 days follow-up after scan
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biodistribution of [11C]CPPC by PET imaging
Time Frame: 1 day
|
Image analysis of PET imaging obtained of patients and healthy participants.
The PET compartmental model fits will be applied to the regional time activity curves (TACs) will be first assessed visually before the relative goodness of fit will be assessed using the statistical F test.
|
1 day
|
Cognitive function as assessed by the NIH Toolbox Cognition Battery (NIHTB-CB)
Time Frame: 1 day
|
NIH Toolbox Cognition Battery (NIHTB-CB), which is an iPad-based instrument assessing five cognitive sub-domains: Language, Executive Function, Episodic Memory, Processing Speed, and Working Memory.
Score range 59 - 140, higher score means better cognition.
|
1 day
|
Neuro-psychological assessment as assessed by the The Rey-Osterrieth complex figure test (ROCF)
Time Frame: 1 day
|
The Rey-Osterrieth complex figure test (ROCF) is a neuro-psychological assessment in which participants are asked to reproduce a complicated line drawing, first by copying it freehand (recognition), and then drawing from memory (recall).
Scoring of drawings is based on the 36-point scoring system (0 being the worst score and 36 the best).
|
1 day
|
Global cognitive function as assessed by the Mini-Mental State Exam (MMSE)
Time Frame: 1 day
|
The MMSE is a measure of global cognitive function, scores range from 0-30, a lower score indicates greater cognitive impairment.
|
1 day
|
Dementia as assessed by the Clinical Dementia Rating (CDR) scale
Time Frame: 1 day
|
The Clinical Dementia Rating Dementia Staging Instrument minimum score = 0, maximum score = 18.
Low scores indicate less problems.
|
1 day
|
Hospital Anxiety and Depression Scale (HADS) score
Time Frame: 1 day
|
Scoring for the Hospital Anxiety and Depression scale is 0-21; Normal (0-7); Borderline Abnormal Case (8-10); and Abnormal Case (11-21) higher score indicates worse outcome.
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Licia Luna, M.D., Ph.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Chronic Disease
- Post-Infectious Disorders
- COVID-19
- Post-Acute COVID-19 Syndrome
Other Study ID Numbers
- IRB00361674
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID Long-Haul
-
Lundquist Institute for Biomedical Innovation at...RecruitingLong Haul COVID or Post Acute Sequella of COVID - PASC (U09.9)United States
-
Endourage, LLCRecruitingLong COVID | Long Covid19 | Post-Acute COVID-19 | Long Haul COVID | Long-Haul COVID-19 | Post-Acute COVID-19 SyndromeUnited States
-
Hôpital Européen MarseilleWithdrawn
-
Beth Israel Deaconess Medical CenterNot yet recruitingLong COVID | COVID Long-Haul | Post-Acute Sequelae of COVID-19
-
Johns Hopkins UniversityCanon Medical Systems, USAEnrolling by invitationCOVID-19 | COVID Long-HaulUnited States
-
Children's Hospital of Orange CountyInnovative Health SolutionsRecruitingCOVID-19 | Post-Concussion Syndrome | COVID Long-HaulUnited States
-
National Institute of Geriatrics, Rheumatology...Medical Research Agency, PolandRecruitingChronic Fatigue Syndrome | COVID-19, Long HaulPoland
-
Beth Israel Deaconess Medical CenterCompleted
-
Miami VA Healthcare SystemNot yet recruiting
-
University of North Carolina, Chapel HillRecruitingAnosmia | Olfaction Disorders | Post-Acute COVID-19 Syndrome | Long Haul COVID-19United States
Clinical Trials on [11C]CPPC Injection
-
Johns Hopkins UniversityPrecision MolecularTerminatedAmyotrophic Lateral SclerosisUnited States
-
Johns Hopkins UniversityUnited States Department of DefenseNot yet recruiting
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Columbia UniversityCompleted
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Completed
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States